Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.33

-0.4%

Nov 26 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (8274)	5/6/2003 6:46:00 PM
From: Icebrg	Read Replies (1) of 52153

Peter >> This is interesting. I predict we are going to hear a lot more about the retinoblastoma (Rb) pathway over the next few years, although I don't know of any public biotechs currently doing much with Rb (Titan and Onyx have dabbled with it I think).>> Thanks for pointing that out. I would have missed it. :-). As a matter of fact Titan's share price has been relatively strong over the last couple of days going from 1.60 to 1.90 under much higher turnover than normal. There might be a connection to the research you referred to. On the other hand RB94, as the product is called, does not seem to have been considered as one of their hotter properties. On the website they say that they are looking for any further development to be funded from external sources. (Which is of course completely in line with Titan's general modus of operation). Erik

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next